Liquidia Corporation Stock 12‑Month Price Target Raised to $52.71, Implies 97% Upside
Liquidia Corporation's average stock price target increased from $52.14 to $52.71, with a range of $33 to $70. This implies 97% upside from the Oct. 13 closing price. The consensus rating remains 'Buy' among 9 analysts, with 5 Buys and 4 Holds.
How this was made
The 30-second read
Why it matters
Analyst target revisions can shift short‑term sentiment but lack a concrete catalyst.
Market read
Small‑cap biotech news with modest trading relevance.
What to watch
No new clinical data or regulatory events accompany the target change.
Background
Liquidia Corp is a biotech focused on drug delivery platforms; price target updates are routine analyst activity.
Ticker impact
Analyst consensus price target for Liquidia Corp was raised to $52.71, implying ~97% upside from the recent close.
potential modest upside as investors adjust valuations
The change reflects analyst opinion rather than a corporate event; impact depends on market perception of the new target.
Market effects
Minor effect on biotech sector as target revisions are common.
Limited to US biotech investors.
Low
Counterpoint
Target raise may be overly optimistic given the company's pipeline risk.
Key entities
- companyLiquidia Corporation
Biotech firm whose price target was raised.
